Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331

Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard-risk B-acute lymphoblastic leukemia (ALL). METHODS: AALL0331 en...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Mattano, Leonard A., Devidas, Meenakshi, Maloney, Kelly W., Wang, Cindy, Friedmann, Alison M., Buckley, Patrick, Borowitz, Michael J., Carroll, Andrew J., Gastier-Foster, Julie M., Heerema, Nyla A., Kadan-Lottick, Nina S., Matloub, Yousif H., Marshall, David T., Stork, Linda C., Loh, Mignon L., Raetz, Elizabeth A., Wood, Brent L., Hunger, Stephen P., Carroll, William L., Winick, Naomi J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2021
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274747/
https://ncbi.nlm.nih.gov/pubmed/33739852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02370
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi